

# Fifth Annual Report on Schizophrenia Pharmacotherapy in VA

FY 2003

Douglas L. Leslie, Ph.D. and Robert Rosenheck, M.D.

VA Connecticut Mental Illness Research, Education and Clinical Center; Northeast Program Evaluation Center, West Haven VAMC; and the Departments of Psychiatry and Epidemiology/Public Health, Yale School of Medicine, New Haven, CT

The authors would like to acknowledge the Drug Benefit Management System in Hines, Illinois for supplying the prescription drug information used in this report.

Address correspondence to:

Douglas L. Leslie, Ph.D.  
NEPEC/182  
950 Campbell Ave.  
West Haven, CT 06516

## Abstract

**Background:** Pharmacotherapy is the cornerstone of effective treatment for schizophrenia. This report presents a profile of the use of antipsychotic medications in the treatment of schizophrenia in the Department of Veterans Affairs nationwide.

**Methods:** Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters with a diagnosis of schizophrenia during fiscal year (FY) 2003. All VA prescription drug records for antipsychotic medications written during FY 2003 were then collected for these patients. Patients who received a prescription for an antipsychotic medication were identified. Taking the last antipsychotic prescription during this period and going back seven days, all antipsychotic medications that were prescribed and the amount prescribed for each patient receiving an antipsychotic were identified. Measures of polypharmacy and compliance with PORT recommendations were constructed from these data, as well as indicators reflecting the use of atypical antipsychotics, and compared with the values from FY 2002.

**Results:** Of the 79,617 patients in the final sample with schizophrenia who received at least one prescription for an antipsychotic medication, 6,704 (8.4%) met criteria for polypharmacy. This proportion is down 0.5% from the FY 2002 level. The majority of patients (50,832 or 63.8%) were dosed within the PORT recommended range, while 12,223 (15.4%) were dosed above the PORT recommendations, an increase of 0.5% over the FY 2002 level. Of the patients who received atypical antipsychotics (65,717 or 82.5%), most received either risperidone (24,521 or 37.3%) or olanzapine (24,042 or 36.6%) Fewer received quetiapine (13,930 or 21.2%), and far fewer received ziprasidone

(3,196 or 4.9%), clozapine (2,097 or 3.2%) or aripiprazole (1.3%). Compared to FY 1999 levels, the first year for which a report is available, there has been a dramatic shift from conventional to atypical antipsychotic medications.

Conclusions: A higher proportion of patients prescribed conventional antipsychotic medications was dosed within the PORT recommendations in FY 2003 than in previous years. However, the percentages of patients receiving atypical drugs who dosed outside the PORT range increased in FY 2003. The proportion of patients receiving more than one antipsychotic medication fell slightly to 8.4%. The number of outpatients diagnosed with schizophrenia who received an atypical antipsychotic continues to grow over time, with most of the increase due to increasing use of quetiapine and ziprasidone.

## I. Introduction

Pharmacotherapy has long been the cornerstone of treatment for schizophrenia. As health care systems respond to pressures to reduce the costs of care, there is a growing concern that quality be systematically monitored and preserved. Performance assessment based on clinically derived practice guidelines provides one mechanism for evaluating the quality of care in a clinical practice or organization. The Schizophrenia Patient Outcomes Research Team (PORT) has developed one widely respected set of guidelines for the treatment of schizophrenia (1).

The Veterans Health Administration of the Department of Veteran Affairs (VA) has not been immune to pressures to reduce health care costs. In 1995, VA experienced a major reorganization in which 22 distinct geographically based Veterans Integrated Service Networks (VISNs) were created, each responsible for the veteran population within its boundaries. An associated goal of the reorganization was to shift the focus of care away from acute inpatient care and towards more ambulatory and primary care in order to improve the accessibility of services and to address anticipated budget reductions (2). Between 1995 and 1999, total mental health expenditures declined by 13%, even without adjustment for inflation (3).

Pharmacologic treatment of schizophrenia has changed in recent years with the introduction of newer atypical antipsychotic medications. These medications (i.e. clozapine, olanzapine, risperidone, quetiapine, and, most recently, ziprasidone and aripiprazole) are equally or more effective than conventional antipsychotic medications and have substantially superior side effect profiles. However, these medications are

considerably more expensive than conventionals, with annual costs averaging \$3,000 - \$5,000, 10 times the \$300 average annual cost of treatment with haloperidol.

As part of an ongoing effort to monitor quality of mental health care in VA (4-7), this report serves three functions: 1) it examines the extent to which pharmacotherapeutic care for patients diagnosed with schizophrenia conforms to the schizophrenia PORT treatment guidelines, 2) it investigates the availability of atypical antipsychotics to patients in VA, and 3) it tracks changes over time in these aspects of pharmacotherapeutic care for schizophrenia.

## II. Methods

### *Sources of data*

Data for the study come from national VA administrative databases. First, all VA outpatients diagnosed with schizophrenia during fiscal year (FY) 2003 (October 1, 2002 to September 30, 2003) were identified. Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters in a specialty mental health outpatient clinic with a primary or secondary diagnosis of schizophrenia (ICD-9 codes 295.00 – 295.99). The outpatient encounter file, a national database of information concerning all outpatient clinic stops in VA, was used to identify these patients. Next, prescription drug records for antipsychotic medications for these patients during FY2003 were collected from the Drug Benefit Management System in Hines, Illinois.

## *Measures*

First, for each patient who received a prescription for an antipsychotic medication, the last prescription for an antipsychotic medication in FY2003 was identified as the index prescription. All prescriptions for antipsychotic medications written during the week prior to the index prescription were then identified. Next, chlorpromazine (CPZ) equivalents were calculated for each prescription for a conventional antipsychotic medication based on the updated PORT dosing algorithms (A. Lehmann, personal communication). CPZ equivalents were summed over all conventional antipsychotic prescriptions during the week to assess guideline adherence. If the total daily CPZ equivalent for all conventional antipsychotics prescribed during the week was greater than the PORT recommendation (1000 mg), the patient was identified as being dosed too high. For the atypical antipsychotics, the total daily dosage for each medication prescribed during the week was calculated. If the total dosage of any atypical was greater than the PORT recommendation, the patient was identified as being dosed too high.<sup>1</sup> In addition, a patient was also identified as being dosed too high if they were prescribed the maximum PORT recommended dose of one atypical *and* were also prescribed any amount of a second atypical.

Although prescribing multiple antipsychotic medications is not addressed in the PORT guidelines, polypharmacy generally is not recommended for schizophrenia

---

<sup>1</sup> The maximum PORT recommended dose for atypical antipsychotic medications are as follows: clozapine 600 mg/day, olanzapine 20 mg/day, quetiapine 450 mg/day and risperidone 6 mg/day.

patients because additional medications may exacerbate side effects while doing little to alleviate symptoms (8, 9). Patients who were prescribed more than one antipsychotic medication during the week were identified as receiving polypharmacy. In addition, the subgroup of patients whose polypharmacy consisted of receiving both an atypical and a conventional antipsychotic medication was examined.

### *Analysis*

Data analysis proceeded in several steps. First, the proportion of patients with the following characteristics were determined: 1) those who received multiple antipsychotic medications, 2) those whose dose was within the PORT recommended range, 3) those who were dosed above the PORT recommendation with any medication, 4) those who were dosed above the PORT recommendation with a conventional antipsychotic, 5) those who were dosed above the PORT recommendation with an atypical antipsychotic, 6) those who received any atypical antipsychotic, and 7) through 12) those who received the specific atypical antipsychotic medications clozapine, olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole among patients receiving any atypical. Means of these measures were calculated by station and by VISN, as well as the percent change from their FY 2002 levels.

### III. Results

Table 1 shows characteristics of the sample. Of the 79,617 patients diagnosed with schizophrenia during FY 2002 who received at least one prescription for an antipsychotic medication from a VA pharmacy, very few were treated with multiple antipsychotic medications (8.4%). A higher proportion (15.4%) was prescribed a dose

that was higher than the PORT recommendation, with most of these patients being dosed too high on an atypical antipsychotic medication. The majority (82.5%) of patients received an atypical antipsychotic. This represents an increase of 23.7% from the FY 1999 figure, the first year of these schizophrenia pharmacotherapy reports (Figure 1). Among patients prescribed an atypical, most received either risperidone (37.3%) or olanzapine (36.6%), with smaller proportions receiving quetiapine (21.2%), and much smaller proportions receiving ziprasidone (4.9%), clozapine (3.2%) or aripiprazole (1.3%).

Tables 2 and 3 report pharmacy measures at the level of the VISN and the facility, respectively. The coefficient of variation at the bottom of each table indicates the amount of variation among VISNs and facilities. At both the VISN level and the facility level, variation was relatively high for the percentage of patients prescribed clozapine or aripiprazole. Variation was small for the percentage of patients prescribed an atypical antipsychotic medication and the percentage of patients dosed within the PORT recommended range.

#### IV. Discussion

This study profiled pharmacologic treatment of patients with schizophrenia in VA. The proportion of patients who were treated with more than one antipsychotic medication, who were dosed above the schizophrenia PORT recommended dosage, and who were prescribed an atypical antipsychotic medication were determined. Only a small proportion (8.4%) of patients were prescribed multiple antipsychotic treatment regimens, while a higher percentage (15.4%) were dosed above PORT guidelines. A



majority of patients (82.5%) were prescribed an atypical antipsychotic, most often olanzapine or risperidone.

In previous work, we performed logistic regressions to explore the effects of patient and facility characteristics on the likelihood that patients with a diagnosis of schizophrenia who are prescribed an antipsychotic received an atypical medication, were dosed outside of the PORT recommended range or were prescribed polypharmacy (10-12). We found that older patients, Blacks and patients with a service connected disability were generally less likely to be prescribed an atypical, while patients with a comorbid mental health diagnosis were more likely to receive these medications. Older patients and those with a comorbid mental health diagnosis were less likely to be dosed above PORT guidelines, and older patients and Blacks were less likely to be prescribed multiple antipsychotic medications. The facility characteristics that we included in our models, which included measures of academic emphasis, reliance on inpatient care and fiscal stress, were generally not significant predictors of our quality measures.

A limitation of the analyses presented in this report relates to the difficulty in measuring prescribing patterns using administrative prescription data. Prescriptions may last for varying lengths of time. Patients with multiple prescriptions may run out of their medications and need to see their doctor to refill their prescriptions at different times. We collect all prescription drug records during a one-week period, but a longer time frame may be necessary to identify all of the drugs a particular patient is taking. Hence, our measures of polypharmacy or whether a patient is dosed above PORT guidelines may be underestimated.

While the proportions of patients diagnosed with schizophrenia who are prescribed multiple antipsychotic medications or who are prescribed a dose that exceeds PORT recommended range are fairly small, these phenomena are still a concern. These medications are studied extensively before they are approved for use, but trials typically do not include combinations with other antipsychotics or abnormally high doses. Hence, the effects of these treatment regimens are unknown. More research is needed to investigate why physicians are prescribing in this manner.

## References

1. Lehman AF, Steinwachs DM, the Co-Investigators of the PORT Project:  
Translating Research into Practice: The Schizophrenia Patient Outcomes  
Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin  
1998; 24(1):1-10
2. Rosenheck R, Horvath T: The Impact of VA Reorganization on Patterns of  
Mental Health Care. Psychiatric Services 1998; 49:53
3. Rosenheck RA, DiLella D: Department of Veterans Affairs National Mental  
Health Program Performance Monitoring System: Fiscal Year 1999 Report. West  
Haven, CT, Northeast Program Evaluation Center, 2000
4. Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a  
Computerized Hospital Database to Monitor Compliance of Pharmacotherapeutic  
Guidelines in the Treatment of Schizophrenia. Psychiatric Services 2000;  
51(6):791-4
5. Leslie DL, Rosenheck RA: Comparing Quality of Mental Health Care in Public  
Sector and Privately Insured Populations: First Efforts and Methodological  
Challenges. Psychiatric Services 2000; 51(5):650-5
6. Rosenheck RA, Cicchetti D: A Mental Health Program Report Card: A  
Multidimensional Approach to Performance Monitoring in Public Sector  
Programs. Community Mental Health Journal 1998; 34(1):85-106

7. Rosenheck RA, Fontana A, Stolar M: Assessing Quality of Care: Administrative Indicators and Clinical Outcome Measures. *Medical Care* 1999; 37(2):180-188
8. Stahl SM: Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret? *Journal of Clinical Psychiatry* 1999; 60(7):425-6
9. Stahl SM: Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. *Journal of Clinical Psychiatry* 1999; 60(8):506-7
10. Leslie DL, Rosenheck RA: Pharmacotherapeutic Treatment of Schizophrenia in the Department of Veterans Affairs: Prescribing Patterns and Guideline Adherence. West Haven, CT, Northeast Program Evaluation Center, 2000, pp 1-19
11. Leslie D, Rosenheck R: The Effects of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. *The Journal of Nervous and Mental Disease* 2001; 189(6): 377-383
12. Leslie D, Rosenheck R: Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System: Individual and Facility Predictors. *Medical Care* 2001; 39(9): 923-933

Table 1. Sample characteristics

Variable	FY 2003		Change from FY 2002	Change from FY 1999
	N	%		
Prescribed any antipsychotic	79,617	100.0%	N/A *	N/A *
Polypharmacy	6,704	8.4%	-0.5%	1.6%
Receiving both atypical and conventional	3,766	4.7%	-1.1%	-0.5%
Dose within PORT guidelines	50,832	63.8%	0.1%	N/A
Dose higher than PORT guidelines	12,223	15.4%	0.5%	0.7%
Conventional antipsychotics	1,372	1.7%	-0.4%	-9.4%
Atypical antipsychotics	10,978	13.8%	0.9%	5.0%
Dose lower than PORT guidelines	16,965	21.3%	-0.7%	-7.5% ***
Conventional antipsychotics	9,115	11.4%	-2.6%	-10.4% ***
Atypical antipsychotics	8,043	10.1%	2.0%	2.9% ***
Received any conventional antipsychotic	17,666	22.2%	-5.7%	-24.2%
Received any atypical antipsychotic	65,717	82.5%	4.7%	23.7%
Clozapine	2,097	3.2%	-0.3%	-2.0%
Olanzapine	24,042	36.6%	-4.3%	-11.8%
Quetiapine	13,930	21.2%	3.6%	16.9%
Risperadone	24,521	37.3%	-0.9%	-6.5%
Ziprasidone	3,196	4.9%	1.2%	N/A **
Aripiprazole	852	1.3%	N/A **	N/A **

\* Data on the percentage of patients with schizophrenia who were prescribed any antipsychotic medication were not available for FY 2003.

\*\* Aripiprazole was new to the market in FY 2003. No patients received this drug before FY 2003. Ziprasidone was approved for use in 2001. No patients received this drug in FY 1999.

\*\*\* Figures from FY 1999 not available. Figures from FY 2000 used instead.

**Figure 1. The Percentage of Patients Prescribed Atypical Antipsychotic Medications**




Table 2a. VISN-level pharmacy measures -- Fiscal Year 2003

		Percent prescribed any antipsychotic	Percent with polypharmacy in past week		Percent dosed within PORT recommended range		Percent dosed higher than PORT recommended range		Percent dosed high on conventionals		Percent dosed high on atypicals		Percent dosed lower than PORT recommended range		Percent dosed low on conventionals		Percent dosed low on atypicals	
VISN	N	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	Change from FY 2003 FY 2002	
1	3,969	N/A	12.7%	-1.2%	59.7%	-0.1%	18.0%	0.3%	6.0%	-0.6%	20.0%	-0.1%	23.1%	-0.1%	54.6%	2.6%	14.0%	2.3%
2	2,279	N/A	9.3%	-0.7%	57.2%	-0.3%	16.6%	0.8%	7.2%	1.8%	19.0%	-0.6%	26.9%	-0.7%	56.6%	0.3%	15.5%	3.5%
3	4,505	N/A	9.3%	-0.9%	63.5%	1.5%	14.6%	-0.8%	8.7%	0.6%	16.1%	-1.6%	22.3%	-0.9%	48.6%	1.3%	11.7%	1.5%
4	4,930	N/A	9.1%	-0.5%	60.9%	1.0%	13.8%	0.2%	6.9%	0.0%	15.6%	-0.2%	26.0%	-1.1%	53.7%	1.8%	13.5%	1.1%
5	2,353	N/A	9.9%	0.5%	63.6%	-2.5%	18.7%	3.4%	11.7%	1.8%	19.3%	3.3%	18.0%	-1.0%	43.9%	-1.3%	11.7%	1.1%
6	3,426	N/A	6.2%	-1.7%	64.0%	-0.1%	14.0%	0.1%	8.7%	-1.1%	15.2%	0.4%	22.4%	-0.2%	51.3%	1.3%	11.8%	2.3%
7	5,331	N/A	6.8%	-0.7%	67.2%	0.5%	13.3%	-0.1%	7.8%	-0.3%	14.1%	-0.1%	19.9%	-0.4%	50.9%	1.2%	11.9%	2.1%
8	7,586	N/A	5.7%	-0.5%	64.3%	-0.2%	11.9%	0.9%	7.1%	-0.2%	12.8%	0.8%	24.1%	-0.9%	54.5%	1.7%	15.2%	1.9%
9	2,916	N/A	7.1%	-0.4%	63.8%	1.4%	13.4%	0.0%	7.3%	1.1%	15.0%	-0.7%	23.2%	-1.6%	49.4%	-2.8%	13.3%	1.9%
10	3,889	N/A	8.6%	0.4%	62.2%	-1.2%	16.0%	2.2%	7.0%	-0.1%	17.7%	2.1%	22.4%	-0.9%	53.7%	0.9%	12.4%	1.9%
11	3,991	N/A	8.4%	0.3%	63.7%	-0.6%	18.3%	2.0%	12.8%	1.3%	18.8%	1.6%	18.6%	-1.3%	45.0%	2.4%	9.9%	1.1%
12	3,184	N/A	7.8%	-1.1%	67.2%	1.5%	11.9%	-0.3%	5.3%	1.0%	13.0%	-1.1%	21.4%	-1.3%	52.0%	-1.7%	13.3%	2.1%
15	3,460	N/A	11.1%	-1.6%	62.6%	0.8%	17.4%	0.2%	8.8%	-0.8%	18.7%	-0.3%	20.7%	-0.9%	49.7%	2.3%	10.9%	1.0%
16	6,691	N/A	8.8%	-0.5%	66.0%	-1.9%	16.3%	1.0%	9.3%	0.7%	17.2%	0.9%	18.2%	1.0%	47.5%	3.0%	11.0%	2.0%
17	3,086	N/A	8.7%	0.9%	65.4%	-0.7%	18.7%	0.9%	7.6%	0.8%	20.2%	0.6%	16.5%	-0.2%	51.4%	-0.2%	9.6%	1.8%
18	2,270	N/A	6.3%	0.1%	65.6%	-1.5%	10.6%	1.4%	4.4%	0.1%	11.8%	1.5%	24.1%	0.1%	59.6%	-1.3%	14.6%	2.9%
19	1,791	N/A	10.2%	-1.9%	63.4%	1.2%	15.6%	-1.8%	5.9%	-2.1%	17.3%	-1.9%	21.9%	0.3%	56.0%	4.1%	11.9%	2.6%
20	3,021	N/A	7.1%	-0.6%	65.2%	0.3%	15.0%	-0.6%	6.1%	-1.5%	16.4%	-0.8%	20.1%	0.1%	55.1%	2.8%	11.4%	2.4%
21	3,485	N/A	10.1%	-0.4%	62.7%	0.4%	18.4%	0.7%	6.9%	1.0%	20.2%	0.0%	19.6%	-1.3%	55.5%	1.2%	10.5%	1.4%
22	4,528	N/A	7.8%	-0.1%	65.7%	1.2%	16.1%	0.0%	7.0%	-1.2%	17.6%	-0.3%	18.6%	-1.2%	47.7%	0.5%	11.5%	1.3%
23	2,926	N/A	9.0%	-0.8%	62.6%	0.3%	17.9%	1.2%	7.6%	-1.5%	19.6%	1.2%	20.0%	-1.5%	51.9%	-0.5%	11.3%	0.5%
Min			5.7%	-1.9%	57.2%	-2.5%	10.6%	-1.8%	4.4%	-2.1%	11.8%	-1.9%	16.5%	-1.6%	43.9%	-2.8%	9.6%	0.5%
Max			12.7%	0.9%	67.2%	1.5%	18.7%	3.4%	12.8%	1.8%	20.2%	3.3%	26.9%	1.0%	59.6%	4.1%	15.5%	3.5%
Mean	3,791		8.6%	-0.5%	63.6%	0.0%	15.5%	0.6%	7.6%	0.0%	16.9%	0.2%	21.3%	-0.7%	51.9%	0.9%	12.2%	1.8%
Std. Dev.	1,442		1.7%	0.7%	2.4%	1.1%	2.4%	1.1%	1.9%	1.1%	2.6%	1.2%	2.7%	0.7%	4.0%	1.7%	1.6%	0.7%
Coeff. of Var.	0.38		0.20	-8.1%	0.04	-9.1%	0.16	1.7%	0.25	5.4%	0.15	-4.7%	0.13	-2.0%	0.08	-6.9%	0.13	1.6%

Table 2b. VISN-level pharmacy measures -- Fiscal Year 2003 (continued)

		Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
		Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
VISN	N	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002
1	3,969	21.7%	-5.7%	83.9%	4.1%	5.7%	-0.3%	30.7%	-0.6%	20.0%	3.0%	29.3%	0.7%	4.4%	0.7%	1.1%	N/A
2	2,279	26.8%	-7.6%	78.3%	6.1%	2.8%	-0.4%	26.8%	-2.1%	18.0%	3.5%	30.6%	3.1%	2.4%	1.2%	1.8%	N/A
3	4,505	27.4%	-6.0%	78.5%	4.4%	2.1%	0.4%	28.0%	-1.3%	13.3%	3.1%	35.0%	1.3%	2.9%	1.1%	0.8%	N/A
4	4,930	29.9%	-6.2%	76.2%	5.7%	1.7%	-0.2%	27.3%	0.6%	17.7%	2.1%	28.6%	1.6%	3.4%	1.3%	0.4%	N/A
5	2,353	18.6%	-4.7%	86.1%	3.9%	1.4%	-0.3%	32.8%	-1.4%	16.7%	3.6%	33.3%	0.6%	5.4%	1.0%	1.7%	N/A
6	3,426	26.2%	-5.4%	77.4%	3.5%	1.8%	0.0%	24.6%	-3.5%	14.8%	5.3%	33.7%	1.1%	4.8%	0.8%	0.2%	N/A
7	5,331	19.6%	-5.4%	84.5%	4.0%	2.0%	-0.3%	28.5%	-4.7%	20.4%	6.6%	30.1%	1.8%	5.6%	0.7%	0.6%	N/A
8	7,586	21.8%	-6.7%	81.6%	5.9%	1.2%	0.0%	37.7%	-1.0%	15.8%	4.3%	25.6%	1.2%	2.8%	1.1%	0.8%	N/A
9	2,916	26.8%	-5.7%	77.8%	5.2%	2.0%	-0.2%	24.2%	-2.8%	16.3%	4.4%	31.7%	1.8%	5.6%	1.5%	0.6%	N/A
10	3,889	23.7%	-5.9%	81.6%	5.9%	5.2%	-0.2%	29.1%	-1.3%	20.7%	5.3%	24.1%	0.0%	4.2%	1.3%	1.4%	N/A
11	3,991	23.9%	-7.9%	81.8%	7.3%	3.5%	0.1%	31.0%	0.1%	13.4%	3.1%	34.1%	3.5%	2.3%	1.2%	0.3%	N/A
12	3,184	20.0%	-5.9%	84.0%	4.2%	3.7%	-0.3%	26.9%	-1.1%	16.1%	3.5%	35.9%	0.5%	3.6%	0.5%	1.6%	N/A
15	3,460	23.8%	-5.7%	83.3%	4.3%	2.1%	-0.2%	29.7%	-1.5%	18.4%	2.5%	32.3%	0.7%	4.2%	1.8%	1.0%	N/A
16	6,691	18.8%	-3.2%	85.8%	2.6%	1.7%	-0.1%	29.8%	-1.3%	18.3%	3.2%	34.3%	-1.5%	4.8%	1.4%	1.1%	N/A
17	3,086	16.2%	-4.0%	87.5%	3.2%	3.1%	-0.2%	34.3%	-1.4%	18.6%	4.1%	30.8%	-0.8%	4.2%	1.6%	1.5%	N/A
18	2,270	19.9%	-4.5%	84.1%	4.2%	1.4%	0.2%	28.8%	-3.5%	16.1%	3.7%	34.0%	1.2%	4.5%	1.5%	1.9%	N/A
19	1,791	21.8%	-6.5%	83.4%	3.9%	5.0%	-0.4%	34.7%	-3.8%	15.5%	2.7%	28.0%	2.9%	3.2%	1.2%	2.1%	N/A
20	3,021	19.4%	-5.2%	84.3%	4.1%	3.1%	0.4%	28.2%	-4.5%	19.2%	6.3%	29.2%	-0.2%	5.6%	0.2%	2.6%	N/A
21	3,485	19.6%	-6.0%	85.7%	5.0%	2.8%	-0.3%	41.3%	-0.3%	16.5%	1.8%	25.6%	2.0%	3.2%	1.6%	1.0%	N/A
22	4,528	19.2%	-5.9%	84.4%	5.0%	2.3%	-0.1%	22.7%	-1.4%	22.3%	2.7%	35.9%	2.0%	3.8%	1.5%	1.4%	N/A
23	2,926	20.7%	-4.8%	84.4%	3.3%	4.3%	-0.2%	34.3%	-1.4%	17.1%	3.4%	27.0%	-0.7%	4.5%	1.7%	1.0%	N/A
Min		16.2%	-7.9%	76.2%	2.6%	1.2%	-0.4%	22.7%	-4.7%	13.3%	1.8%	24.1%	-1.5%	2.3%	0.2%	0.2%	
Max		29.9%	-3.2%	87.5%	7.3%	5.7%	0.4%	41.3%	0.6%	22.3%	6.6%	35.9%	3.5%	5.6%	1.8%	2.6%	
Mean	3,791	22.2%	-5.7%	82.6%	4.6%	2.8%	-0.1%	30.1%	-1.8%	17.4%	3.7%	30.9%	1.1%	4.1%	1.2%	1.2%	
Std. Dev.	1,442	3.6%	1.1%	3.2%	1.1%	1.3%	0.2%	4.5%	1.5%	2.3%	1.3%	3.5%	1.3%	1.0%	0.4%	0.6%	
Coeff. of Var.	0.38	0.16	4.9%	0.04	-22.3%	0.47	-1.9%	0.15	9.9%	0.13	-23.6%	0.11	-7.7%	0.26	-38.8%	0.53	



Table 3a. Station-level pharmacy measures -- Fiscal Year 2003

VISN	Station	Station name	N	Percent prescribed any antipsychotic		Percent with polypharmacy in past week		Percent dosed within PORT recommended range		Percent dosed higher than PORT recommended range		Percent dosed high on conventionals		Percent dosed high on atypicals		Percent dosed lower than PORT recommended range		Percent dosed low on conventionals		Percent dosed low on atypicals	
				Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002		Change from FY 2002	
				FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002
1	402	TOGUS	452	N/A		17.0%	-2.3%	61.5%	3.5%	18.1%	-0.2%	7.4%	2.1%	19.7%	-1.2%	22.8%	-2.7%	51.2%	-3.0%	11.6%	1.7%
1	405	WHITE RIVER JCT	151	N/A		10.6%	1.8%	60.9%	8.1%	13.2%	-3.6%	6.7%	-0.9%	14.5%	-7.0%	26.5%	-3.9%	71.1%	10.7%	7.7%	0.1%
1	518	BEDFORD	470	N/A		17.0%	-0.4%	54.3%	-3.1%	24.0%	2.6%	8.9%	-0.8%	26.8%	2.9%	23.2%	-0.1%	57.1%	6.4%	12.7%	2.0%
1	523	BOSTON	1,172	N/A		13.8%	-3.4%	59.7%	1.8%	15.6%	-2.2%	5.1%	-0.8%	17.3%	-2.5%	25.3%	0.7%	54.5%	2.6%	17.0%	2.3%
1	608	MANCHESTER	138	N/A		16.7%	5.0%	47.1%	-8.7%	18.1%	9.6%	5.3%	2.9%	20.9%	10.0%	34.8%	-0.9%	63.2%	-2.0%	22.7%	3.2%
1	631	NORTHAMPTON	354	N/A		9.0%	-2.3%	56.5%	-4.3%	22.3%	2.9%	0.0%	-1.4%	25.9%	3.0%	21.2%	1.1%	53.3%	-3.8%	14.8%	4.8%
1	650	PROVIDENCE	400	N/A		11.0%	2.4%	59.5%	-2.1%	22.3%	2.5%	8.6%	0.3%	23.5%	2.0%	18.5%	-1.0%	53.4%	0.7%	13.2%	1.8%
1	689	WEST HAVEN	832	N/A		8.7%	-0.8%	65.1%	-0.1%	14.8%	-0.3%	5.7%	-2.3%	16.4%	-0.5%	20.7%	0.6%	50.8%	5.2%	11.1%	2.7%
2	528	UPSTATE N.Y. HCS	2,279	N/A		9.3%	-0.7%	57.2%	-0.3%	16.6%	0.8%	7.2%	1.8%	19.0%	-0.6%	26.9%	-0.7%	56.6%	0.3%	15.5%	3.5%
3	526	BRONX	513	N/A		5.1%	-2.8%	66.7%	0.0%	12.3%	0.1%	5.6%	-1.8%	13.8%	0.3%	21.2%	-0.5%	52.0%	2.3%	11.8%	2.7%
3	561	EAST ORANGE	1,246	N/A		9.6%	0.4%	63.2%	1.7%	17.5%	1.3%	12.2%	3.0%	18.5%	0.7%	19.7%	-3.1%	48.1%	-2.1%	9.8%	0.8%
3	620	MONTROSE	668	N/A		14.2%	-0.5%	58.2%	-0.9%	20.7%	0.7%	17.8%	3.1%	21.5%	-0.7%	22.0%	0.3%	40.4%	1.4%	12.0%	1.2%
3	630	N.Y. HARBOR HCS	1,465	N/A		8.2%	-1.7%	66.0%	2.7%	11.6%	-1.9%	3.6%	-1.1%	13.7%	-2.7%	22.5%	-1.0%	50.4%	2.5%	12.0%	1.3%
3	632	NORTHPORT	613	N/A		9.8%	0.2%	61.5%	1.7%	11.1%	-3.9%	5.1%	-0.7%	12.4%	-5.7%	28.1%	2.2%	52.6%	4.0%	14.7%	2.8%
4	460	WILMINGTON	243	N/A		7.0%	-4.4%	60.5%	-6.2%	19.8%	4.2%	1.6%	-3.0%	24.7%	6.3%	21.0%	1.8%	54.0%	4.7%	8.9%	1.2%
4	503	JAMES E VAN ZAND	163	N/A		8.6%	-0.6%	58.9%	-1.9%	9.2%	2.3%	5.3%	0.5%	10.4%	2.6%	32.5%	-0.6%	61.4%	5.8%	15.7%	5.3%
4	529	BUTLER	99	N/A		5.1%	-1.7%	61.6%	-0.9%	8.1%	-5.4%	0.0%	-3.0%	10.4%	-7.2%	30.3%	4.3%	64.0%	9.5%	18.2%	6.0%
4	540	CLARKSBURG	210	N/A		9.5%	-0.6%	65.2%	8.0%	11.0%	-2.0%	4.9%	3.1%	12.4%	-4.1%	24.3%	-6.0%	65.9%	-3.8%	13.5%	-1.7%
4	542	COATESVILLE	481	N/A		11.6%	3.8%	68.0%	3.5%	16.6%	1.9%	13.3%	3.5%	16.6%	1.4%	15.8%	-5.2%	43.3%	-4.9%	9.0%	-3.4%
4	562	ERIE	184	N/A		10.9%	-4.2%	57.1%	11.1%	9.8%	2.2%	0.0%	-1.3%	12.1%	1.6%	33.7%	-13.4%	74.5%	-2.7%	17.4%	-1.7%
4	595	LEBANON	567	N/A		10.2%	-1.9%	63.1%	5.8%	12.0%	-2.5%	6.8%	-0.3%	12.9%	-3.9%	25.4%	-3.7%	50.8%	-3.9%	12.6%	1.5%
4	642	PHILADELPHIA	1,282	N/A		6.9%	-1.7%	61.2%	0.9%	13.5%	-0.4%	8.0%	-0.8%	15.4%	-0.7%	25.7%	-0.5%	51.0%	1.3%	13.6%	3.4%
4	646	PITTSBURGH-UNIV	1,201	N/A		11.5%	1.7%	58.0%	-4.5%	15.1%	1.0%	4.9%	-0.2%	18.0%	0.8%	28.1%	4.0%	53.7%	8.4%	14.6%	2.6%
4	693	WILKES BARRE	500	N/A		6.4%	-1.5%	58.4%	4.5%	13.2%	0.2%	11.4%	2.0%	13.7%	-0.1%	29.2%	-4.3%	55.7%	2.4%	16.2%	-3.0%
5	512	BALTIMORE	1,058	N/A		11.2%	1.5%	62.5%	-1.8%	18.9%	2.6%	12.8%	2.4%	19.3%	2.1%	18.8%	-1.0%	39.7%	-4.4%	11.8%	2.1%
5	613	MARTINSBURG	329	N/A		8.5%	-2.1%	62.6%	0.7%	19.5%	5.2%	4.5%	-1.5%	21.9%	5.6%	19.1%	-5.4%	57.6%	-3.0%	9.0%	-3.3%
5	688	WASHINGTON	966	N/A		8.8%	0.4%	65.1%	-4.4%	18.2%	3.8%	13.2%	2.8%	18.5%	3.7%	16.7%	0.4%	45.6%	5.6%	12.6%	1.5%
6	517	BECKLEY	128	N/A		9.4%	-1.4%	63.3%	0.2%	7.0%	-0.7%	2.3%	-1.7%	8.8%	0.0%	29.7%	-1.1%	58.1%	4.1%	14.3%	-1.1%
6	558	DURHAM	466	N/A		6.9%	-0.8%	59.7%	-1.2%	18.2%	-2.2%	15.7%	-6.3%	18.8%	0.4%	22.5%	3.9%	53.6%	9.5%	8.7%	4.0%
6	565	FAYETTEVILLE NC	467	N/A		3.9%	-3.1%	66.4%	0.3%	11.3%	-1.3%	6.4%	-0.6%	12.2%	-1.5%	22.3%	0.1%	60.3%	-6.0%	14.5%	6.7%
6	590	HAMPTON	561	N/A		3.2%	-1.9%	68.4%	3.4%	13.5%	-0.5%	10.9%	2.6%	14.1%	-1.6%	18.2%	-3.3%	48.3%	-3.9%	7.3%	0.0%
6	637	ASHEVILLE-OTEEEN	200	N/A		3.0%	-2.7%	60.5%	1.6%	13.5%	3.2%	6.0%	3.5%	16.0%	1.9%	26.5%	-4.4%	45.9%	5.9%	17.4%	-7.2%
6	652	RICHMOND	417	N/A		8.6%	-1.2%	64.0%	-4.7%	12.0%	1.9%	6.5%	-1.4%	13.1%	3.1%	24.2%	2.5%	50.5%	-0.4%	14.9%	6.0%
6	658	SALEM	539	N/A		8.9%	-2.1%	65.7%	1.5%	14.7%	0.0%	9.5%	-1.8%	15.8%	0.6%	20.2%	-1.7%	42.5%	1.1%	8.7%	-0.2%
6	659	SALISBURY	648	N/A		6.5%	-0.2%	61.1%	-1.3%	15.4%	0.9%	4.3%	-1.7%	17.7%	1.0%	24.1%	0.7%	59.6%	2.0%	13.9%	2.6%
7	508	ATLANTA	1,064	N/A		7.7%	-2.6%	68.0%	1.7%	13.2%	-2.6%	4.6%	-3.7%	14.7%	-2.0%	19.3%	0.5%	45.8%	3.9%	11.8%	1.6%
7	509	AUGUSTA	677	N/A		4.0%	0.2%	64.4%	7.4%	17.7%	-2.2%	6.6%	-0.3%	19.7%	-4.4%	18.0%	-5.5%	49.6%	-9.6%	10.8%	2.0%
7	521	BIRMINGHAM	683	N/A		7.9%	0.1%	66.5%	-0.2%	15.2%	-0.4%	9.2%	3.1%	16.1%	-1.5%	18.7%	1.0%	55.7%	5.0%	10.1%	2.5%
7	534	CHARLESTON	532	N/A		9.4%	-3.2%	69.7%	0.3%	10.2%	1.0%	5.4%	-3.7%	10.8%	2.8%	21.1%	-0.4%	54.6%	8.4%	9.4%	-1.0%
7	544	COLUMBIA SC	660	N/A		12.6%	-1.6%	61.5%	-1.8%	15.9%	3.1%	10.5%	2.1%	16.6%	3.8%	23.0%	-1.3%	56.2%	7.3%	12.7%	-0.1%
7	557	DUBLIN	396	N/A		1.8%	-3.7%	76.3%	-2.3%	8.6%	2.8%	7.9%	-1.6%	8.6%	3.6%	15.2%	-0.5%	55.3%	0.5%	11.0%	1.4%
7	619	MONTGOMERY	916	N/A		4.3%	2.5%	69.2%	-2.9%	9.6%	0.7%	7.7%	2.6%	9.6%	0.1%	21.3%	2.3%	53.0%	-5.4%	16.4%	6.0%
7	679	TUSCALOOSA	403	N/A		5.7%	0.7%	63.5%	-0.1%	15.9%	1.1%	12.2%	-0.7%	17.2%	1.5%	21.1%	-0.8%	43.2%	-1.1%	9.1%	1.9%
8	516	BAY PINES	803	N/A		6.1%	-1.0%	61.1%	-1.7%	19.4%	2.7%	7.3%	-1.3%	21.8%	2.9%	19.9%	-1.0%	55.8%	2.2%	10.5%	2.2%
8	546	MIAMI	1,083	N/A		6.9%	-1.7%	59.0%	0.7%	19.7%	-0.6%	17.9%	1.6%	19.4%	-1.5%	22.0%	-0.4%	45.1%	2.6%	13.7%	1.3%
8	548	W PALM BEACH	414	N/A		9.9%	2.2%	61.1%	-3.7%	26.3%	5.3%	3.4%	-7.0%	28.7%	5.7%	13.0%	-1.2%	41.4%	1.8%	8.0%	2.3%
8	573	N FL/S GA HCS	1,225	N/A		7.2%	-1.2%	70.9%	2.4%	11.0%	-0.8%	6.8%	-0.6%	11.6%	-1.0%	18.5%	-1.9%	52.2%	2.2%	9.5%	0.2%
8	672	SAN JUAN	2,623	N/A		3.2%	-0.5%	66.6%	-0.4%	3.4%	0.2%	2.7%	-0.2%	3.5%	0.3%	30.1%	0.1%	65.8%	-1.1%	21.8%	3.3%
8	673	TAMPA	1,438	N/A		6.5%	0.9%	61.0%	-1.6%	14.2%	3.5%	6.1%	0.6%	16.6%	3.2%	24.9%	-2.3%	50.2%	2.5%	13.6%	0.9%
9	581	HUNTINGTON	262	N/A		5.7%	1.4%	55.0%	-3.4%	16.4%	5.3%	6.1%	4.7%	19.8%	5.5%	29.4%	-1.2%	66.7%	-6.9%	15.9%	3.2%
9	596	LEXINGTON-LEESTO	287	N/A		8.7%	-1.9%	61.3%	0.9%	17.4%	-3.4%	4.1%	-0.7%	19.1%	-3.7%	21.3%	2.5%	65.3%	10.5%	12.0%	0.3%
9	603	LOUISVILLE	413	N/A		7.7%	-0.2%	64.2%	0.9%	9.7%	0.4%	4.0%	2.2%	10.8%	-0.6%	26.6%	-1.7%	67.3%	-2.0%	13.6%	2.8%
9	614	MEMPHIS	562	N/A		3.2%	-0.1%	69.6%	5.1%	13.7%	-1.7%	5.6%	-0.6%	17.0%	-2.8%	16.7%	-3.8%	43.8%	-4.5%	4.1%	-1.2%
9	621	MOUNTAIN HOME	285	N/A		4.9%	-0.4%	63.2%	0.0%	9.5%	3.0%	7.4%	3.2%	10.5%	3.5%	27.7%	-3.0%	54.4%	2.4%	18.4%	-2.7%
9	626	VA MID TENN HCS	1,107	N/A		9.4%	-0.8%	63.5%	1.3%	14.0%	-0.5%	10.0%	1.1%	14.6%	-1.6%	23.1%	-1.0%	39.8%	-4.8%	15.7%	4.4%
10	538	CHILLICOTHE	646	N/A		15.5%	1.2%	59.3%	-1.6%	14.6%	2.2%	9.7%	2.1%	14.5%	1.2%	27.2%	0.0%	49.3%	0.4%	15.1%	2.3%
10	539	CINCINNATI	512	N/A		7.6%	-1.9%	65.8%	-1.2%	16.8%	1.7%	9.5%	2.8%	17.4%	0.9%	17.8%	-0.1%	48.6%	3.1%	12.3%	2.0%
10	541	CLEVELAND-WADE P	1,899	N/A		7.8%	0.3%	60.7%	-0.8%	18.6%	3.4%	6.1%	-1.0%	21.8%	3.9%	21.2%	-2.8%	56.2%	1.3%	9.2%	-0.2%
10	552	DAYTON	435	N/A		4.6%	2.0%	66.9%	-0.8%	12.2%	-0.8%	8.0%	-2.5%	12.1%	1.9%	50.6%	-2.4%	13.3%	3.7%	13.3%	3.7%
10	757	COLUMBUS-IOC	397	N/A		6.5%	1.3%	64.0%	-4.0%	8.8%	1.1%	1.5%	-1.2%	9.7%	0.9%	27.5%	3.1%	60.6%	1.1%	21.8%	8.0%
11	506	ANN ARBOR HCS	458	N/A		8.1%	-0.2%	61.1%	1.4%	23.1%	-0.3%	8.2%	0.7%	25.8%	-0.6%	16.6%	-1.2%	46.9%	-0.7%	7.9%	1.0%
11	515	BATTLE CREEK	875	N/A		12.3%	2.4%	61.7%	-2.9%	18.5%	5.7%	14.5%	1.6%	17.8%	6.1%	20.8%	-2.3%	52.7%	7.8%	9.4%	1.7%

				Percent prescribed any antipsychotic		Percent with polypharmacy in past week		Percent dosed within PORT recommended range		Percent dosed higher than PORT recommended range		Percent dosed high on conventionals		Percent dosed high on atypicals		Percent dosed lower than PORT recommended range		Percent dosed low on conventionals		Percent dosed low on atypicals	
VSN		Station	Station name	N	Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from		
					FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	
11	550	ILLIANA HCS DANV	485	N/A			6.0%	2.2%	60.2%	-6.1%	21.0%	4.7%	8.7%	1.4%	24.0%	4.6%	19.2%	1.1%	44.4%	1.8%	
11	553	DETROIT VAMC	952	N/A			7.0%	-0.5%	68.1%	-0.7%	15.9%	0.6%	17.9%	3.5%	14.7%	-0.1%	16.4%	0.0%	34.7%	-0.5%	
11	583	INDIANAPOLIS-10T	435	N/A			7.1%	-3.5%	66.7%	4.0%	16.8%	-1.9%	12.6%	-0.2%	17.5%	-2.1%	17.0%	-1.9%	46.0%	-0.6%	
11	610	NORTHERN INDIANA	520	N/A			8.8%	0.5%	61.2%	-0.2%	18.7%	2.1%	14.4%	0.6%	19.4%	2.2%	21.0%	-1.6%	42.5%	3.9%	
11	655	SAGINAW	266	N/A			6.8%	-0.5%	66.2%	4.8%	14.3%	0.1%	3.1%	0.4%	17.1%	-0.7%	20.3%	-4.6%	52.3%	-1.0%	
12	537	VA CHICAGO HCS	1,090	N/A			4.2%	-1.6%	67.2%	1.5%	10.1%	1.1%	5.2%	2.2%	10.8%	0.6%	22.8%	-2.7%	55.8%	-0.7%	
12	556	NORTH CHICAGO	239	N/A			5.4%	0.0%	67.8%	0.9%	12.1%	-6.3%	13.7%	9.4%	11.3%	-10.8%	20.5%	4.2%	43.1%	-0.3%	
12	578	HINES	538	N/A			8.0%	-0.1%	71.9%	-0.5%	9.3%	-0.7%	2.3%	-1.1%	10.2%	-0.9%	19.5%	1.4%	53.5%	1.8%	
12	585	IRON MOUNTAIN	148	N/A			27.0%	-1.6%	56.1%	0.2%	18.9%	1.3%	8.5%	2.3%	21.1%	0.6%	25.7%	-1.5%	51.1%	-1.0%	
12	607	MADISON	258	N/A			7.8%	-0.3%	65.5%	4.9%	18.6%	-4.3%	5.3%	-7.7%	21.5%	-3.5%	15.9%	-1.1%	47.7%	-6.3%	
12	676	TOMAH	277	N/A			8.3%	-4.0%	63.9%	-0.9%	19.1%	0.7%	2.9%	-2.4%	23.1%	1.4%	18.8%	0.8%	53.6%	0.3%	
12	695	MILWAUKEE	634	N/A			10.1%	-0.2%	68.0%	3.0%	9.8%	0.3%	5.4%	1.4%	10.5%	-0.7%	23.0%	-3.5%	50.9%	-0.3%	
15	589	VAMC HEARTLAND-W	1,726	N/A			9.2%	-1.5%	62.8%	1.4%	20.5%	0.5%	10.6%	-1.8%	21.7%	0.0%	17.4%	-1.7%	42.7%	1.9%	
15	657	VA HEARTLAND-E V	1,734	N/A			13.1%	-1.6%	62.3%	0.3%	14.3%	-0.1%	7.4%	0.4%	15.5%	-0.6%	23.9%	-0.1%	55.4%	1.9%	
16	502	ALEXANDRIA	560	N/A			12.5%	-5.0%	64.6%	0.5%	21.3%	-4.3%	7.4%	-3.3%	22.4%	-4.8%	14.5%	3.9%	40.7%	12.2%	
16	520	GULF COAST HCS	1,163	N/A			14.5%	0.9%	61.7%	-2.1%	19.9%	1.6%	15.5%	2.2%	19.9%	1.7%	19.9%	0.7%	45.0%	4.2%	
16	564	FAYETTEVILLE AR	296	N/A			9.8%	-4.1%	68.2%	2.9%	16.9%	-0.2%	11.5%	-3.2%	17.3%	1.3%	15.5%	-2.8%	36.5%	-4.6%	
16	580	HOUSTON	1,250	N/A			7.8%	0.3%	67.1%	-0.4%	18.0%	-0.5%	12.3%	1.2%	18.5%	-1.0%	15.1%	0.8%	37.4%	-0.2%	
16	586	JACKSON	568	N/A			8.1%	0.7%	67.8%	-2.0%	13.6%	1.5%	3.2%	0.1%	14.9%	1.0%	19.0%	0.7%	37.9%	-7.5%	
16	598	LITTLE ROCK	682	N/A			6.5%	0.0%	67.4%	0.3%	15.4%	0.7%	7.0%	1.2%	16.8%	0.0%	17.9%	-0.9%	52.4%	-1.0%	
16	623	MUSKOGEE	287	N/A			7.7%	2.1%	66.2%	-3.8%	10.1%	5.3%	2.2%	2.2%	11.2%	5.5%	24.4%	-0.8%	50.0%	-11.4%	
16	629	NEW ORLEANS	842	N/A			6.7%	1.4%	68.2%	-7.1%	17.8%	3.4%	8.7%	0.4%	18.5%	3.5%	14.5%	3.6%	49.5%	9.7%	
16	635	OKLAHOMA CITY	574	N/A			5.7%	-3.9%	71.8%	-2.0%	10.6%	4.0%	6.1%	2.2%	11.4%	4.3%	18.1%	-1.9%	60.5%	7.0%	
16	667	SHREVEPORT	469	N/A			5.3%	-0.7%	58.8%	-4.9%	9.6%	-0.1%	2.7%	-0.7%	11.7%	0.2%	31.8%	5.0%	69.4%	8.4%	
17	549	DALLAS	1,106	N/A			9.0%	0.9%	66.2%	0.6%	15.1%	-0.9%	3.0%	-1.5%	16.6%	-1.2%	19.1%	-0.2%	60.1%	-1.0%	
17	671	SAN ANTONIO	902	N/A			10.0%	1.0%	65.3%	-1.6%	18.6%	2.1%	8.3%	1.0%	20.6%	2.2%	16.9%	-0.1%	46.1%	3.0%	
17	674	VA CENTRAL TEXAS	1,078	N/A			7.3%	0.9%	64.6%	-1.3%	22.4%	1.9%	13.5%	3.5%	12.2%	1.1%	13.5%	-0.5%	48.2%	-4.1%	
18	501	NEW MEXICO HCS	449	N/A			4.7%	0.0%	67.9%	0.6%	12.2%	2.1%	1.6%	-3.1%	13.9%	2.0%	20.3%	-2.5%	61.9%	-5.5%	
18	504	AMARILLO HCS	148	N/A			6.1%	-3.5%	48.6%	1.6%	5.4%	-1.2%	5.2%	2.1%	5.1%	-3.5%	45.9%	-0.4%	74.1%	6.0%	
18	519	WEST TEXAS HCS	153	N/A			4.6%	0.9%	69.3%	-13.1%	15.0%	12.3%	0.0%	0.0%	17.0%	13.6%	15.7%	-0.1%	62.5%	-4.2%	
18	644	PHOENIX	753	N/A			7.6%	0.2%	67.9%	-1.2%	8.5%	1.6%	6.9%	1.5%	8.8%	1.9%	23.8%	-0.9%	55.2%	-2.1%	
18	649	NORTHERN ARIZONA	164	N/A			4.3%	-1.7%	58.5%	-4.1%	7.9%	-1.8%	2.8%	0.1%	9.0%	-2.7%	34.1%	6.5%	61.1%	0.6%	
18	678	SOUTHERN ARIZONA	385	N/A			7.8%	2.4%	63.1%	-4.7%	15.8%	1.0%	8.1%	-1.3%	16.4%	1.2%	62.2%	-0.3%	16.4%	3.4%	
18	756	EL PASO HCS	218	N/A			5.0%	-0.7%	72.0%	4.0%	7.8%	-2.5%	0.0%	-1.9%	10.2%	-3.0%	21.6%	-0.2%	52.5%	1.6%	
19	436	FORT HARRISON	218	N/A			5.5%	-5.6%	64.7%	7.3%	17.0%	-4.0%	15.2%	9.9%	17.1%	-6.6%	18.8%	-4.6%	48.5%	1.1%	
19	442	CHEYENNE	110	N/A			16.4%	-2.3%	62.7%	1.9%	14.5%	-5.1%	3.6%	-2.1%	16.7%	-5.8%	23.6%	3.0%	60.7%	17.9%	
19	554	DENVER	763	N/A			9.0%	-1.5%	62.5%	0.1%	14.9%	-1.7%	5.7%	-5.4%	17.1%	-0.6%	23.7%	2.1%	52.4%	4.5%	
19	575	GRAND JUNCTION	141	N/A			14.9%	-1.0%	52.5%	-6.2%	13.9%	-5.7%	5.1%	-1.0%	17.1%	-7.9%	33.3%	10.3%	61.5%	14.6%	
19	660	SALT LAKE CITY H	410	N/A			9.5%	-2.2%	67.6%	3.1%	13.2%	-1.4%	1.7%	-2.6%	14.3%	-1.2%	20.0%	-2.1%	67.8%	-7.9%	
19	666	SHERIDAN	149	N/A			16.1%	1.4%	65.1%	1.1%	25.5%	4.9%	10.0%	7.1%	26.9%	2.1%	10.1%	-7.6%	55.0%	3.0%	
20	463	ALASKA HCS & RO	69	N/A			2.9%	1.4%	69.6%	-6.6%	15.9%	-2.0%	11.1%	0.0%	16.1%	-2.5%	14.5%	8.5%	44.4%	11.1%	
20	531	BOISE	249	N/A			9.2%	-1.2%	61.8%	-4.2%	13.3%	0.6%	3.8%	-1.2%	14.8%	0.6%	25.3%	4.0%	56.6%	3.3%	
20	648	PORTLAND	705	N/A			4.7%	-0.2%	63.7%	-1.6%	15.9%	2.6%	8.9%	-1.1%	17.4%	3.4%	20.7%	-0.9%	54.4%	0.3%	
20	653	VA ROSEBURG HCS	326	N/A			7.4%	2.6%	66.0%	-3.1%	15.3%	-0.7%	5.3%	-0.2%	16.7%	-1.6%	19.3%	4.1%	45.6%	5.6%	
20	663	PUGET SOUND HCS	1,122	N/A			7.4%	-1.5%	64.8%	2.9%	16.6%	-1.8%	5.5%	-2.1%	18.3%	-2.3%	19.1%	-1.3%	56.2%	4.9%	
20	668	SPOKANE	202	N/A			8.4%	-3.0%	75.2%	7.0%	9.4%	-4.7%	11.1%	5.1%	9.1%	-5.6%	13.3%	-2.9%	55.6%	-5.1%	
20	687	WALLA WALLA	128	N/A			9.4%	0.4%	58.6%	-1.4%	13.3%	2.3%	2.6%	-3.7%	16.2%	4.2%	28.1%	-3.9%	59.0%	2.7%	
20	692	WHITE CITY	220	N/A			9.1%	0.4%	68.2%	-0.3%	11.4%	-2.7%	2.9%	-2.9%	12.4%	-2.5%	20.5%	2.0%	62.9%	0.0%	
21	358	MANILA	139	N/A			35.3%	4.0%	41.0%	0.0%	7.9%	-0.4%	1.2%	-0.9%	10.8%	-2.6%	55.4%	-0.2%	84.9%	2.6%	
21	459	HONOLULU	463	N/A			9.1%	-1.1%	64.8%	3.8%	13.4%	-0.1%	5.2%	0.3%	15.4%	-0.6%	21.8%	-3.7%	56.3%	-1.1%	
21	570	CENTRAL CALIFORN	300	N/A			5.7%	-0.2%	68.0%	3.9%	19.0%	-0.4%	1.8%	0.2%	13.0%	-3.8%	45.5%	-7.8%	6.0%	0.0%	
21	612	NCHC MARTINEZ	917	N/A			8.6%	-0.7%	62.4%	-2.2%	17.0%	0.7%	9.9%	-0.1%	17.9%	0.9%	21.3%	1.3%	50.3%	2.9%	
21	640	PALO ALTO-PALO A	968	N/A			10.5%	-0.1%	60.6%	1.1%	25.3%	0.7%	12.8%	5.9%	26.4%	-1.5%	14.9%	-2.1%	51.8%	1.8%	
21	654	SIERRA NEVADA HC	182	N/A			6.0%	0.2%	73.1%	-2.2%	11.5%	-0.1%	4.0%	-7.7%	12.7%	0.8%	15.4%	1.7%	43.5%	8.9%	
21	662	SAN FRANCISCO	516	N/A			9.9%	-0.1%	64.1%	-2.4%	17.2%	3.4%	0.0%	0.4%	19.4%	3.5%	19.4%	-0.8%	52.5%	2.9%	
22	593	LAS VEGAS	413	N/A			7.7%	2.6%	66.3%	-2.7%	16.0%	2.2%	3.7%	2.0%	17.3%	1.2%	17.9%	0.8%	48.1%	-9.5%	
22	600	VA LONG BEACH HC	668	N/A			10.3%	-1.8%	64.7%	0.8%	18.7%	3.0%	8.3%	-1.3%	20.1%	3.5%	17.2%	-3.7%	42.4%	-3.9%	
22	605	LOMA LINDA	607	N/A			9.1%	-1.1%	64.9%	1.7%	15.8%	-0.4%	9.4%	-2.1%	17.2%	0.1%	19.6%	-1.6%	48.7%	3.3%	
22	664	VA SAN DIEGO HCS	840	N/A			9.5%	1.1%	60.4%	4.1%	17.1%	-2.6%	8.7%	-2.1%	18.7%	-4.3%	23.5%	-1.3%	56.0%	7.2%	
22	691	GREATER LA HCS	2,000	N/A			5.9%	-0.3%	68.5%	0.9%	14.9%	-0.2%	5.2%	-0.8%	16.5%	-0.7%	17.0%	-0.7%	44.1%	-1.5%	
23	437	FARGO	179	N/A			8.9%	-0.5%	62.6%	-3.0%	18.4%	2.2%	0.0%	0.0%	20.4%	2.0%	19.6%	0.6%	72.0%	4.1%	
23	438	SIOUX FALLS	217	N/A			13.4%	1.0%	63.6%	-0.4%	17.1%	2.3%	8.0%	0.5%	18.1%	1.8%	20.7%	-0.9%	50.0%	2.8%	
23	568	FORT MEADE	213	N/A			16.0%	4.0%	57.7%	-4.0%	15.5%	4.4%	7.6%	-0.2%	17.5%	6.0%	26.8%	-0.4%	51.5%	4.8%	
23	618	MINNEAPOLIS	770	N/A			6.6%	-0.7%	65.3%	0.8%	17.8%	1.7%	7.6%	0.2%	19.0%	1.2%	17.1%	-2.6%	53.4%	-1.3%	

				Percent prescribed any antipsychotic	Percent with polypharmacy in past week		Percent dosed within PORT recommended range		Percent dosed higher than PORT recommended range		Percent dosed high on conventionals		Percent dosed high on atypicals		Percent dosed lower than PORT recommended range		Percent dosed low on conventionals		Percent dosed low on atypicals		
				Change from FY 2003 FY 2002	Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		Change from FY 2003 FY 2002		
VISN	Station	Station name	N		FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	
23	636	VA NEB-WESTERN I	1,252	N/A	8.7%	-2.9%	61.9%	1.9%	18.0%	-0.6%	8.3%	-3.5%	19.8%	-0.4%	20.6%	-1.4%	47.7%	-3.3%	12.2%	1.4%	
23	656	ST CLOUD	295	N/A	8.1%	2.1%	61.4%	-2.3%	19.7%	3.3%	7.2%	0.6%	21.8%	3.0%	20.0%	-0.6%	60.9%	3.5%	7.8%	0.5%	
Min					1.8%	-5.6%	41.0%	-13.1%	3.4%	-6.3%	0.0%	-7.7%	3.5%	-10.8%	10.1%	-13.4%	34.7%	-11.4%	3.0%	-7.2%	
Max					35.3%	5.0%	76.3%	11.1%	26.3%	12.3%	17.9%	9.9%	28.7%	13.6%	55.4%	10.3%	84.9%	17.9%	26.3%	13.2%	
Mean					622	8.8%	-0.5%	63.5%	-0.1%	15.1%	0.6%	7.0%	0.0%	16.5%	0.3%	21.9%	-0.5%	53.1%	1.2%	12.3%	1.9%
Std. Dev.					469	4.3%	1.9%	5.0%	3.5%	4.3%	2.8%	4.1%	2.8%	4.7%	3.4%	6.1%	3.0%	8.5%	5.1%	3.9%	2.8%
Coeff. of Var.					0.75	0.49	4.7%	0.08	-9.9%	0.29	-6.9%	0.59	9.7%	0.28	-7.7%	0.28	-4.1%	0.16	-9.4%	0.31	-17.0%

Table 3b. Station-level pharmacy measures -- Fiscal Year 2003 (continued)

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002
1	402	TOGUS	452	26.8%	-6.6%	82.1%	2.7%	6.2%	-0.9%	34.3%	1.0%	19.5%	-0.4%	23.9%	3.8%	4.9%	0.5%	0.9%	N/A
1	405	WHITE RIVER JCT	151	29.8%	-12.6%	77.5%	14.3%	4.6%	0.6%	20.5%	2.1%	15.2%	0.0%	31.1%	7.9%	9.3%	3.7%	0.7%	N/A
1	518	BEDFORD	470	23.8%	-6.4%	81.9%	4.3%	8.7%	1.0%	24.9%	1.2%	25.7%	1.4%	29.4%	2.0%	3.2%	0.0%	1.9%	N/A
1	523	BOSTON	1,172	20.1%	-4.9%	85.7%	2.8%	4.2%	-1.4%	30.7%	-0.5%	25.9%	4.7%	28.7%	-3.6%	3.3%	0.4%	0.9%	N/A
1	608	MANCHESTER	138	27.5%	-5.8%	79.7%	8.4%	2.9%	-0.2%	29.0%	4.2%	23.2%	5.4%	30.4%	-0.6%	1.4%	-0.1%	3.6%	N/A
1	631	NORTHAMPTON	354	16.9%	-4.0%	86.2%	2.3%	6.8%	0.8%	34.7%	-0.9%	15.8%	2.9%	31.9%	-1.6%	3.1%	0.4%	0.0%	N/A
1	650	PROVIDENCE	400	14.5%	-5.0%	89.3%	3.8%	5.0%	0.4%	33.5%	-1.1%	17.0%	5.1%	35.0%	1.2%	5.0%	0.4%	1.0%	N/A
1	689	WEST HAVEN	832	23.2%	-6.5%	82.0%	5.0%	6.4%	-0.3%	31.1%	-3.5%	12.0%	2.7%	28.7%	4.3%	6.1%	1.4%	1.0%	N/A
2	528	UPSTATE N.Y. HCS	2,279	26.8%	-7.6%	78.3%	6.1%	2.8%	-0.4%	26.8%	-2.1%	18.0%	3.5%	30.6%	3.1%	2.4%	1.2%	1.8%	N/A
3	526	BRONX	513	24.4%	-6.5%	79.1%	4.0%	2.1%	1.7%	28.7%	-0.7%	11.3%	0.5%	34.5%	-0.1%	3.3%	1.5%	1.2%	N/A
3	561	EAST ORANGE	1,246	25.0%	-7.6%	80.4%	6.2%	2.2%	0.4%	22.7%	-0.4%	12.4%	4.2%	43.7%	2.7%	3.1%	1.1%	0.2%	N/A
3	620	MONTROSE	668	31.9%	-3.6%	78.7%	2.9%	3.9%	0.3%	27.5%	-2.0%	18.3%	4.5%	31.0%	-0.6%	0.9%	0.5%	0.9%	N/A
3	630	N.Y. HARBOR HCS	1,465	26.4%	-6.5%	77.5%	4.1%	0.8%	-0.1%	29.7%	-1.1%	13.6%	2.1%	32.4%	1.4%	4.3%	1.4%	1.4%	N/A
3	632	NORTHPORT	613	32.0%	-3.6%	76.3%	3.5%	2.8%	1.1%	34.6%	-3.4%	10.6%	4.1%	28.5%	0.9%	1.1%	1.0%	0.0%	N/A
4	460	WILMINGTON	243	25.9%	-3.8%	78.2%	1.5%	0.0%	-0.5%	33.7%	-2.3%	13.2%	0.8%	27.6%	2.5%	4.9%	-1.5%	1.2%	N/A
4	503	JAMES E VAN ZAND	163	35.0%	-13.5%	70.6%	11.3%	0.6%	-0.2%	28.2%	3.6%	16.0%	4.4%	25.2%	4.4%	2.5%	0.1%	1.8%	N/A
4	529	BUTLER	99	25.3%	-6.5%	77.8%	6.6%	1.0%	-0.9%	37.4%	0.8%	14.1%	-2.2%	23.2%	3.0%	3.0%	3.0%	1.0%	N/A
4	540	CLARKSBURG	210	19.5%	-7.4%	84.8%	8.8%	2.4%	0.0%	30.5%	-4.6%	28.6%	10.8%	24.8%	-2.2%	4.3%	3.8%	0.0%	N/A
4	542	COATESVILLE	481	18.7%	-4.5%	87.7%	6.0%	1.9%	0.0%	29.7%	4.0%	19.3%	-3.3%	33.9%	3.8%	6.2%	2.1%	1.0%	N/A
4	562	ERIE	184	27.7%	-18.2%	81.0%	14.1%	1.6%	-0.1%	23.9%	1.8%	19.0%	4.5%	34.8%	5.7%	3.3%	2.1%	0.5%	N/A
4	595	LEBANON	567	31.2%	-8.3%	76.7%	6.7%	1.4%	-0.1%	29.5%	3.6%	12.9%	3.4%	31.4%	-1.8%	3.4%	1.3%	0.0%	N/A
4	642	PHILADELPHIA	1,282	32.3%	-7.8%	71.8%	6.7%	0.1%	-0.2%	27.5%	-0.1%	17.6%	1.5%	26.7%	3.6%	2.3%	1.3%	0.0%	N/A
4	646	PITTSBURGH-UNIV	1,201	32.2%	-2.6%	76.0%	3.5%	3.6%	-0.4%	23.6%	-1.1%	20.6%	2.9%	27.5%	1.3%	3.7%	1.4%	0.4%	N/A
4	693	WILKES BARRE	500	33.4%	-5.4%	71.6%	3.8%	2.8%	0.0%	25.6%	2.4%	13.0%	2.8%	29.6%	-2.0%	1.8%	0.5%	0.2%	N/A
5	512	BALTIMORE	1,058	24.3%	-4.7%	82.8%	4.8%	1.6%	-0.1%	35.2%	-0.3%	13.3%	2.8%	31.9%	2.7%	4.6%	0.9%	0.6%	N/A
5	613	MARTINSBURG	329	20.1%	-4.1%	84.8%	3.9%	1.5%	-0.7%	35.6%	3.3%	18.2%	1.4%	23.4%	-4.8%	9.4%	2.1%	0.3%	N/A
5	688	WASHINGTON	966	11.8%	-4.5%	90.3%	2.8%	1.2%	-0.3%	29.3%	-4.1%	20.0%	5.0%	38.2%	0.0%	4.9%	0.6%	3.5%	N/A
6	517	BECKLEY	128	33.6%	-4.9%	71.1%	1.1%	1.6%	0.0%	18.8%	-2.0%	11.7%	6.3%	40.6%	-0.9%	1.6%	0.0%	0.0%	N/A
6	558	DURHAM	466	30.0%	-4.7%	74.0%	3.4%	1.5%	-0.5%	22.7%	-1.5%	9.2%	2.3%	36.1%	2.8%	6.9%	1.2%	0.0%	N/A
6	565	FAYETTEVILLE NC	467	16.7%	-7.4%	84.4%	4.5%	0.4%	-0.1%	21.0%	-7.6%	11.1%	6.4%	53.3%	4.9%	1.3%	0.7%	0.0%	N/A
6	590	HAMPTON	561	26.2%	-4.8%	75.9%	3.0%	1.4%	0.2%	29.6%	-5.5%	12.1%	2.9%	28.0%	2.7%	5.7%	2.5%	0.2%	N/A
6	637	ASHEVILLE-OTEEEN	200	30.5%	-6.6%	72.0%	6.9%	0.0%	0.0%	19.0%	-1.0%	24.0%	5.7%	24.0%	-3.4%	5.5%	3.8%	0.0%	N/A
6	652	RICHMOND	417	25.7%	-4.6%	78.7%	1.7%	0.7%	0.2%	28.1%	-5.6%	18.9%	4.6%	31.7%	3.0%	2.4%	-0.3%	1.2%	N/A
6	658	SALEM	539	33.2%	-5.5%	72.9%	3.8%	4.8%	0.3%	24.9%	4.3%	11.9%	2.9%	29.7%	-4.0%	4.3%	0.1%	0.2%	N/A
6	659	SALISBURY	648	21.8%	-4.1%	82.1%	3.0%	1.9%	0.3%	24.5%	-6.7%	21.5%	11.3%	29.2%	-0.7%	7.3%	-0.5%	0.0%	N/A
7	508	ATLANTA	1,064	20.3%	-4.1%	85.1%	1.4%	1.8%	0.1%	29.2%	-5.2%	18.8%	5.9%	34.3%	0.3%	2.6%	-0.2%	0.8%	N/A
7	509	AUGUSTA	677	17.9%	-10.8%	84.6%	10.2%	6.1%	-0.9%	36.0%	1.1%	13.7%	7.3%	23.3%	4.2%	6.8%	-0.9%	0.1%	N/A
7	521	BIRMINGHAM	683	19.2%	-3.7%	85.4%	3.4%	0.7%	-0.3%	28.4%	-10.0%	25.0%	6.1%	31.5%	7.2%	1.9%	0.0%	1.3%	N/A
7	534	CHARLESTON	532	24.4%	-4.2%	81.6%	0.9%	3.4%	-0.3%	24.6%	0.8%	12.6%	-1.7%	30.1%	-0.7%	13.0%	1.3%	1.3%	N/A
7	544	COLUMBIA SC	660	23.2%	-5.4%	82.3%	1.2%	0.3%	0.1%	30.3%	-4.4%	27.3%	4.3%	24.1%	1.9%	7.4%	2.0%	0.0%	N/A
7	557	DUBLIN	396	9.6%	-3.8%	91.4%	2.0%	0.3%	0.3%	24.2%	-1.6%	22.5%	8.1%	28.5%	-10.1%	16.2%	3.4%	0.3%	N/A
7	619	MONTGOMERY	916	12.8%	-4.9%	89.4%	5.7%	0.2%	0.1%	28.9%	-10.0%	24.9%	13.0%	34.6%	3.6%	2.7%	0.5%	0.1%	N/A
7	679	TUSCALOOSA	403	34.5%	-4.3%	70.7%	5.3%	4.7%	-0.6%	19.9%	-3.9%	14.6%	4.3%	28.8%	2.7%	1.7%	0.9%	1.5%	N/A
8	516	BAY PINES	803	20.5%	-6.6%	82.2%	5.2%	1.5%	0.2%	36.7%	-1.8%	15.1%	3.4%	27.8%	1.8%	3.9%	1.5%	0.5%	N/A
8	546	MIAMI	1,083	24.7%	-5.8%	80.6%	4.3%	1.8%	-0.1%	27.6%	-2.4%	16.7%	3.1%	31.1%	0.3%	2.8%	1.1%	2.2%	N/A
8	548	W PALM BEACH	414	14.0%	-10.4%	90.8%	10.7%	2.4%	-0.7%	41.5%	1.5%	17.9%	5.9%	30.0%	5.8%	3.9%	-0.4%	0.2%	N/A
8	573	N FL/S GA HCS	1,225	20.3%	-6.3%	84.0%	4.7%	2.0%	0.0%	34.7%	0.8%	14.0%	2.7%	32.2%	0.3%	3.5%	1.1%	0.7%	N/A
8	672	SAN JUAN	2,623	18.5%	-4.9%	83.2%	4.5%	0.2%	-0.1%	47.5%	-3.1%	19.5%	6.0%	16.1%	0.6%	0.9%	0.6%	0.5%	N/A
8	673	TAMPA	1,438	29.6%	-10.2%	74.4%	9.8%	1.5%	0.4%	29.3%	1.4%	9.7%	3.8%	30.9%	2.6%	4.7%	2.2%	0.8%	N/A
9	581	HUNTINGTON	262	25.2%	-3.4%	79.0%	4.0%	0.0%	0.0%	22.1%	-2.5%	19.1%	6.8%	32.8%	-1.7%	5.3%	1.0%	0.8%	N/A
9	596	LEXINGTON-LEESTO	287	17.1%	-0.1%	87.5%	-0.3%	1.4%	-0.2%	28.9%	-3.7%	19.5%	0.3%	39.7%	0.5%	2.1%	1.3%	0.3%	N/A
9	603	LOUISVILLE	413	24.5%	-4.9%	80.4%	3.9%	2.7%	0.3%	24.7%	-2.0%	11.4%	4.2%	36.3%	-0.7%	7.5%	2.2%	0.5%	N/A
9	614	MEMPHIS	562	31.7%	-4.5%	69.9%	3.6%	1.8%	-0.3%	18.7%	-2.1%	10.9%	2.6%	30.8%	2.7%	8.5%	0.7%	0.5%	N/A
9	621	MOUNTAIN HOME	285	23.9%	-5.7%	80.0%	5.1%	0.7%	-0.5%	22.1%	-2.2%	19.3%	1.5%	29.5%	4.4%	8.8%	1.5%	0.7%	N/A

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002
9	626	VA MID TENN HCS	1,107	28.8%	-8.7%	77.6%	8.1%	2.7%	-0.5%	26.6%	-3.5%	18.5%	6.4%	28.5%	3.0%	3.5%	1.7%	0.7%	N/A
10	538	CHILLICOTHE	646	33.6%	-5.3%	79.1%	7.2%	6.3%	-0.2%	18.9%	-1.1%	26.9%	4.1%	23.4%	4.5%	4.5%	-1.4%	1.5%	N/A
10	539	CINCINNATI	512	14.5%	-6.5%	88.7%	5.6%	3.7%	-0.2%	32.8%	-1.6%	25.8%	6.2%	20.5%	-5.5%	5.9%	1.2%	4.3%	N/A
10	541	CLEVELAND-WADE P	1,899	25.2%	-6.3%	78.8%	5.2%	6.7%	0.0%	32.5%	0.1%	15.6%	4.1%	22.8%	-1.0%	4.1%	2.6%	0.7%	N/A
10	552	DAYTON	435	20.0%	-2.1%	83.0%	4.3%	1.4%	-0.2%	31.3%	-6.0%	15.9%	4.4%	31.0%	4.2%	4.6%	1.2%	0.5%	N/A
10	757	COLUMBUS-IOC	397	16.6%	-6.1%	87.9%	7.6%	2.0%	0.2%	21.9%	-2.4%	33.5%	11.0%	29.0%	-1.8%	2.3%	-0.5%	1.3%	N/A
11	506	ANN ARBOR HCS	458	21.4%	-4.0%	85.4%	2.9%	5.2%	-0.2%	39.1%	-5.7%	11.4%	0.9%	29.0%	6.8%	2.2%	2.2%	0.0%	N/A
11	515	BATTLE CREEK	875	25.1%	-14.6%	84.2%	15.7%	4.3%	-0.4%	32.8%	6.7%	15.9%	3.9%	32.2%	5.8%	1.6%	0.8%	0.6%	N/A
11	550	ILLIANA HCS DANV	485	26.0%	-4.4%	79.2%	6.6%	1.6%	0.5%	31.1%	-0.6%	13.4%	3.6%	31.8%	2.3%	1.9%	0.7%	0.0%	N/A
11	553	DETROIT VAMC	952	20.6%	-7.8%	82.7%	6.6%	4.6%	0.7%	25.5%	-0.6%	12.7%	3.6%	42.5%	3.2%	0.5%	0.2%	0.3%	N/A
11	583	INDIANAPOLIS-10T	435	20.0%	-4.5%	83.0%	-0.1%	2.8%	-0.1%	30.8%	-3.8%	14.5%	2.4%	29.0%	-2.0%	9.4%	4.1%	0.5%	N/A
11	610	NORTHERN INDIANA	520	30.8%	-5.7%	74.4%	4.7%	1.5%	0.0%	33.8%	0.6%	9.4%	1.7%	30.6%	1.8%	2.5%	2.1%	0.2%	N/A
11	655	SAGINAW	266	24.4%	-7.8%	81.2%	6.5%	2.3%	0.5%	24.8%	-1.4%	16.9%	5.3%	38.0%	2.8%	0.4%	-0.1%	0.0%	N/A
12	537	VA CHICAGO HCS	1,090	15.8%	-7.3%	86.6%	5.5%	0.7%	0.0%	27.1%	-2.2%	17.4%	3.3%	38.2%	2.1%	3.0%	0.2%	1.8%	N/A
12	556	NORTH CHICAGO	239	21.3%	-3.7%	81.6%	2.8%	2.5%	0.9%	32.2%	1.8%	11.3%	5.9%	32.2%	-7.5%	4.2%	0.9%	1.3%	N/A
12	578	HINES	538	16.0%	-2.6%	87.2%	1.1%	1.7%	-1.3%	27.3%	-0.9%	16.7%	4.1%	42.2%	-1.6%	3.9%	1.8%	0.2%	N/A
12	585	IRON MOUNTAIN	148	31.8%	-3.5%	83.1%	0.8%	1.4%	-0.1%	26.4%	-3.8%	19.6%	-1.7%	45.9%	3.3%	2.7%	2.0%	0.0%	N/A
12	607	MADISON	258	17.1%	-4.1%	84.9%	1.8%	15.1%	-0.6%	28.3%	-2.6%	15.9%	1.1%	24.0%	3.3%	2.7%	-1.5%	4.3%	N/A
12	676	TOMAH	277	24.9%	-3.8%	79.8%	2.0%	9.4%	-1.0%	27.8%	0.6%	9.4%	0.6%	34.7%	2.1%	1.8%	-2.4%	0.7%	N/A
12	695	MILWAUKEE	634	26.3%	-9.4%	79.7%	8.1%	4.3%	0.0%	23.7%	0.0%	17.2%	6.2%	31.1%	-0.2%	5.5%	1.3%	2.1%	N/A
15	589	VAMC HEARTLAND-W	1,726	21.3%	-7.0%	84.8%	5.3%	2.8%	-0.2%	25.5%	-1.6%	19.2%	4.1%	33.4%	-0.7%	5.4%	2.6%	1.7%	N/A
15	657	VA HEARTLAND-E V	1,734	26.4%	-4.5%	81.8%	3.4%	1.4%	-0.2%	33.9%	-1.3%	17.6%	0.9%	31.1%	2.1%	2.9%	1.0%	0.3%	N/A
16	502	ALEXANDRIA	560	14.5%	-3.3%	90.9%	3.1%	3.0%	-1.2%	43.4%	4.4%	13.2%	2.0%	36.3%	-8.5%	1.8%	1.4%	0.7%	N/A
16	520	GULF COAST HCS	1,163	25.0%	-2.5%	83.7%	2.3%	0.9%	-0.1%	28.8%	-0.8%	21.9%	3.5%	35.0%	0.6%	2.4%	0.1%	0.1%	N/A
16	564	FAYETTEVILLE AR	296	17.6%	-9.5%	87.8%	5.8%	1.4%	-0.6%	27.7%	-0.6%	22.0%	0.8%	29.7%	1.8%	7.4%	-0.1%	3.7%	N/A
16	580	HOUSTON	1,250	17.5%	-2.9%	85.9%	2.5%	2.0%	-0.1%	29.4%	-4.3%	18.2%	6.1%	34.2%	-0.7%	4.9%	0.5%	1.5%	N/A
16	586	JACKSON	568	16.7%	-2.2%	87.5%	3.1%	0.9%	-0.3%	28.5%	6.3%	22.7%	0.3%	31.5%	-4.9%	7.0%	0.6%	0.9%	N/A
16	598	LITTLE ROCK	682	21.0%	-4.0%	83.0%	3.8%	5.3%	0.6%	22.6%	-2.7%	15.4%	0.7%	35.0%	2.5%	4.4%	0.7%	2.8%	N/A
16	623	MUSKOGEE	287	16.0%	-1.6%	87.1%	2.3%	2.4%	-0.4%	33.8%	1.0%	20.2%	5.8%	31.0%	-3.4%	4.5%	0.9%	0.0%	N/A
16	629	NEW ORLEANS	842	12.2%	-2.8%	90.6%	2.4%	0.4%	-0.1%	32.3%	-2.6%	13.4%	5.9%	39.9%	-5.2%	8.1%	5.7%	0.4%	N/A
16	635	OKLAHOMA CITY	574	19.9%	-8.1%	83.8%	4.1%	0.3%	0.3%	32.4%	-5.5%	19.7%	6.7%	31.0%	1.7%	1.9%	0.4%	0.2%	N/A
16	667	SHREVEPORT	469	23.7%	2.7%	78.3%	-3.4%	0.6%	-0.1%	20.9%	-4.5%	18.6%	-4.6%	31.6%	-0.6%	7.5%	3.8%	2.6%	N/A
17	549	DALLAS	1,106	15.2%	-3.3%	88.5%	2.5%	3.6%	-0.5%	37.0%	-0.5%	24.0%	4.1%	24.5%	-2.6%	3.8%	2.4%	1.2%	N/A
17	671	SAN ANTONIO	902	21.4%	-4.6%	83.5%	3.3%	1.9%	-0.3%	29.3%	-4.3%	12.0%	5.1%	35.5%	-0.5%	6.9%	2.3%	3.0%	N/A
17	674	VA CENTRAL TEXAS	1,078	12.9%	-4.2%	89.8%	3.7%	3.7%	0.0%	35.6%	-0.1%	18.6%	3.0%	33.3%	1.0%	2.3%	0.1%	0.6%	N/A
18	501	NEW MEXICO HCS	449	14.0%	-7.3%	88.4%	7.0%	2.4%	-0.8%	24.7%	-4.5%	18.5%	6.6%	33.2%	1.0%	7.6%	1.1%	4.2%	N/A
18	504	AMARILLO HCS	148	39.2%	-9.3%	66.9%	6.6%	0.7%	-0.1%	18.9%	-2.4%	23.6%	3.8%	20.9%	1.8%	1.4%	1.4%	1.4%	N/A
18	519	WEST TEXAS HCS	153	15.7%	-6.5%	88.2%	7.7%	0.7%	0.7%	44.4%	-12.0%	19.6%	14.1%	24.2%	4.7%	0.7%	0.7%	0.0%	N/A
18	644	PHOENIX	753	23.1%	-4.2%	83.1%	3.9%	1.9%	0.5%	27.1%	-2.7%	12.1%	1.8%	38.5%	1.0%	4.1%	3.1%	0.9%	N/A
18	649	NORTHERN ARIZONA	164	22.0%	-6.4%	81.7%	4.8%	0.0%	-0.7%	25.0%	-4.1%	17.1%	8.9%	37.2%	-0.9%	1.2%	-0.3%	1.8%	N/A
18	678	SOUTHERN ARIZONA	385	9.6%	0.5%	91.7%	0.0%	1.0%	1.0%	34.5%	-1.9%	19.0%	0.4%	36.9%	0.4%	4.9%	0.1%	2.3%	N/A
18	756	EL PASO HCS	218	27.1%	-3.2%	76.1%	3.0%	0.0%	0.0%	31.2%	-5.4%	11.5%	0.6%	28.0%	4.6%	6.0%	1.4%	0.9%	N/A
19	436	FORT HARRISON	218	15.1%	-8.3%	85.8%	2.4%	0.9%	-0.3%	34.4%	4.2%	19.7%	-2.5%	31.7%	-0.4%	2.8%	0.3%	0.9%	N/A
19	442	CHEYENNE	110	25.5%	-8.9%	81.8%	3.4%	0.9%	-2.0%	37.3%	-9.8%	18.2%	6.4%	25.5%	8.8%	6.4%	0.5%	2.7%	N/A
19	554	DENVER	763	27.8%	-4.9%	78.0%	3.7%	5.1%	-0.2%	31.7%	-4.6%	14.2%	3.5%	26.1%	3.0%	2.6%	0.4%	1.7%	N/A
19	575	GALT JUNCTION	141	27.7%	-11.2%	83.0%	6.8%	0.7%	-0.1%	26.2%	-1.5%	14.9%	7.0%	42.6%	2.1%	1.4%	1.4%	1.4%	N/A
19	660	SALT LAKE CITY H	410	14.4%	-3.8%	90.2%	1.7%	9.8%	-0.4%	37.8%	-6.1%	15.9%	1.0%	26.1%	3.2%	4.9%	3.1%	1.0%	N/A
19	666	SHERIDAN	149	13.4%	-11.6%	89.9%	9.8%	4.0%	1.1%	48.3%	-0.2%	14.1%	1.6%	26.2%	0.4%	1.3%	1.3%	8.7%	N/A
20	463	ALASKA HCS & RO	69	13.0%	-0.4%	89.9%	1.8%	1.4%	1.4%	63.8%	1.1%	4.3%	1.4%	17.4%	2.5%	2.9%	-4.6%	0.0%	N/A
20	531	BOISE	249	21.3%	-5.9%	84.3%	4.2%	3.2%	1.0%	18.1%	-3.6%	26.1%	4.8%	34.5%	-2.6%	4.8%	4.4%	0.8%	N/A
20	648	PORTLAND	705	22.4%	-5.5%	79.7%	5.1%	6.0%	0.5%	27.7%	-8.7%	20.6%	8.9%	17.2%	0.6%	7.0%	0.1%	4.1%	N/A
20	653	VA ROSEBURG HCS	326	17.5%	-2.5%	86.5%	2.9%	1.2%	0.9%	28.2%	-4.9%	22.1%	10.8%	31.0%	-4.7%	4.0%	-0.7%	3.7%	N/A
20	663	PUGET SOUND HCS	1,122	19.3%	-6.9%	84.7%	5.1%	3.1%	0.0%	28.4%	-1.3%	16.5%	4.1%	31.6%	0.6%	5.9%	-0.1%	2.4%	N/A
20	668	SPOKANE	202	8.9%	-8.3%	92.6%	4.0%	0.5%	0.0%	29.7%	-6.8%	25.2%	4.9%	37.1%	4.3%	4.5%	0.8%	2.5%	N/A
20	687	WALLA WALLA	128	30.5%	-1.5%	77.3%	2.3%	0.8%	0.8%	24.2%	-8.8%	14.1%	3.1%	39.1%	8.1%	0.8%	-0.2%	0.0%	N/A
20	692	WHITE CITY	220	15.9%	-1.1%	88.2%	0.3%	0.9%	0.9%	29.5%	-4.4%	18.2%	9.4%	36.8%	-5.9%	7.3%	1.0%	1.8%	N/A

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002	FY 2003	FY 2002
21	358	MANILA	139	61.9%	-4.8%	66.9%	14.8%	0.0%	0.0%	23.7%	4.3%	10.8%	0.4%	32.4%	10.2%	0.0%	0.0%	0.0%	N/A
21	459	HONOLULU	463	20.7%	-6.5%	82.7%	5.1%	1.7%	-0.3%	32.4%	1.6%	21.4%	-0.8%	26.6%	0.0%	5.2%	3.9%	1.1%	N/A
21	570	CENTRAL CALIFORN	300	18.3%	-4.4%	83.7%	3.4%	2.3%	0.1%	41.3%	-0.1%	18.3%	1.8%	23.3%	1.7%	2.0%	0.9%	0.3%	N/A
21	612	NCHC MARTINEZ	917	19.7%	-4.1%	85.2%	3.3%	2.3%	-0.1%	45.0%	-0.5%	16.4%	3.2%	24.0%	0.3%	1.0%	0.1%	0.2%	N/A
21	640	PALO ALTO-PALO A	968	14.6%	-7.6%	90.3%	5.9%	5.4%	-0.7%	49.2%	2.7%	15.1%	0.8%	23.1%	2.2%	2.1%	0.7%	1.4%	N/A
21	654	SIERRA NEVADA HC	182	12.6%	-4.2%	91.2%	3.5%	0.5%	-0.7%	35.7%	-11.0%	17.6%	3.3%	28.6%	4.5%	11.0%	8.4%	0.0%	N/A
21	662	SAN FRANCISCO	516	19.6%	-6.1%	84.9%	3.3%	1.4%	0.0%	34.7%	-6.4%	15.1%	4.2%	30.4%	3.4%	6.0%	2.1%	2.5%	N/A
22	593	LAS VEGAS	413	13.1%	-4.6%	89.8%	5.7%	1.5%	0.3%	38.0%	-2.8%	24.2%	8.3%	24.2%	-0.1%	5.1%	0.0%	1.5%	N/A
22	600	VA LONG BEACH HC	668	19.8%	-7.3%	84.7%	4.8%	3.1%	0.2%	21.4%	-1.1%	23.7%	3.2%	35.3%	1.2%	5.7%	1.3%	1.5%	N/A
22	605	LOMA LINDA	607	19.3%	-5.5%	85.3%	3.8%	2.3%	-0.4%	27.3%	-3.2%	26.4%	3.5%	29.0%	0.4%	2.5%	2.3%	2.3%	N/A
22	664	VA SAN DIEGO HCS	840	26.0%	-8.6%	79.8%	8.6%	1.7%	-0.4%	16.3%	-3.6%	19.3%	4.1%	40.4%	7.2%	4.0%	1.0%	1.4%	N/A
22	691	GREATER LA HCS	2,000	17.5%	-4.7%	84.9%	3.9%	2.4%	-0.1%	21.3%	-0.4%	21.6%	0.8%	38.8%	1.4%	3.2%	1.7%	1.0%	N/A
23	437	FARGO	179	14.0%	-5.0%	90.5%	2.0%	5.6%	0.2%	48.6%	-2.7%	17.9%	7.1%	19.0%	-1.3%	1.1%	-1.6%	1.7%	N/A
23	438	SIOUX FALLS	217	23.0%	-3.1%	83.9%	2.6%	5.1%	-0.3%	29.5%	1.4%	15.7%	4.3%	34.1%	-4.3%	5.5%	2.1%	0.5%	N/A
23	568	FORT MEADE	213	31.0%	-4.5%	77.9%	5.6%	3.3%	-0.4%	15.5%	-2.5%	25.8%	4.2%	36.2%	6.2%	1.9%	-0.4%	1.9%	N/A
23	618	MINNEAPOLIS	770	15.3%	-4.7%	88.1%	3.7%	4.0%	0.0%	39.6%	-0.8%	17.5%	0.3%	23.6%	0.5%	6.0%	3.5%	0.8%	N/A
23	636	VA NEB-WESTERN I	1,252	22.1%	-5.4%	83.0%	2.3%	3.4%	-0.3%	29.8%	-3.1%	16.9%	4.7%	30.2%	-1.7%	5.1%	1.6%	1.3%	N/A
23	656	ST CLOUD	295	23.4%	-3.3%	82.4%	4.8%	8.1%	0.0%	48.5%	2.9%	11.2%	3.7%	14.9%	-1.8%	1.4%	0.3%	0.0%	N/A
Min				8.9%	-18.2%	66.9%	-3.4%	0.0%	-2.0%	15.5%	-12.0%	4.3%	-4.6%	14.9%	-10.1%	0.0%	-4.6%	0.0%	
Max				61.9%	2.7%	92.6%	15.7%	15.1%	1.7%	63.8%	6.7%	33.5%	14.1%	53.3%	10.2%	16.2%	8.4%	8.7%	
Mean			622	22.4%	-5.6%	82.5%	4.6%	2.6%	0.0%	30.1%	-1.8%	17.4%	3.8%	30.8%	1.1%	4.2%	1.1%	1.1%	
Std. Dev.			469	7.3%	2.9%	5.6%	3.0%	2.3%	0.6%	7.6%	3.5%	4.9%	3.1%	6.2%	3.4%	2.6%	1.5%	1.3%	
Coeff. of Var.			0.75	0.32	9.8%	0.07	-23.7%	0.90	-1.9%	0.25	0.1%	0.28	-21.2%	0.20	-13.1%	0.63	-18.6%	1.11	